Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Free Report) have received an average recommendation of “Moderate Buy” from the nine ratings firms that are covering the firm, Marketbeat.com ...

Discover the latest developments in potential ALS treatments with COYA-302 and COYA-303, set to impact the $1.33 billion ...

Amylyx Pharmaceuticals, Inc. (AMLX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates ...

AB19001 also prohibited the use of Radicava or Radicava ORS (edaravone), ALS therapies approved in the U.S., and Relyvrio (sodium phenylbutyrate and taurursodiol), which has been removed from the U.S.

Amylyx is trying to resurrect its ALS portfolio after it was forced to withdraw Relyvrio (sodium phenylbutyrate and taurursodiol) from the U.S. and Canadian markets after it failed its Phase III ...

CAMBRIDGE, Mass. - Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX), a $245.1 million market cap biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical ...

The US Food and Drug Administration (FDA) has lifted a clinical hold on Amylyx Pharmaceuticals’ Phase I trial of AMX0114 in amyotrophic lateral sclerosis (ALS). The lift allows Amylyx to open US ...

Amylyx expects LUMINA to begin in early 2025. The company in March said its ALS drug Relyvrio had failed a late-stage clinical trial, and the stock has sunk more than 78% over the past year.